Kestra Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Kestra Advisory Services's REGN Position: Q2 2026 in Review
Kestra Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 35% in Q2 2026, selling an estimated $1.07M and leaving 2,893 shares worth $1.8M. The position accounts for 0.01% of the portfolio, ranked #1426.
Kestra Advisory Services first reported a position in REGN in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.03M in Q3 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Kestra Advisory Services held 2,893 shares of Regeneron Pharmaceuticals worth $1.8M as of Q2 2026.
- Kestra Advisory Services sold 1,577 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.07M.
- Regeneron Pharmaceuticals made up 0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #1426 holding.
- Kestra Advisory Services first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
- Kestra Advisory Services's Regeneron Pharmaceuticals position peaked at $7.03M in Q3 2024.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.